Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

On July 3, Janssen-Cilag, a company of Johnson & Johnson (NYSE:JNJ), reported applying to the European Medicines Agency to ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Novo Nordisk has submitted a new, higher dose of its obesity treatment, Wegovy, for approval to the European Medicines Agency ...

The study will recruit patients in the US and Europe. Earlier this year, Purespring announced that the European Medicines ...

During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in ...

The demand for obesity drugs in India surges as Eli Lilly and Novo Nordisk vie for market share. Meanwhile, President Trump ...

This non-dilutive financing includes an upfront payment of $275 million in cash and up to $25 million in milestone payments contingent upon European Medicines Agency/EMA approval of Aspaveli for C3 ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Authorities such as the BfArM and the European Medicines Agency grant authorisation only after a positive benefit-risk ratio ...

Danish pharmaceutical company Novo Nordisk (NVO) on Tuesday said that it has submitted an application to the European ...